Cargando…

Cohort profile: Copenhagen Hospital Biobank - Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases

PURPOSE: The aim of Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC) is to establish a cohort that can accelerate our understanding of CVD initiation and progression by jointly studying genetics, diagnoses, treatments and risk factors. PARTICIPANTS: The CHB-CVDC is a large genomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Laursen, Ina H, Banasik, Karina, Haue, Amalie D, Petersen, Oscar, Holm, Peter C, Westergaard, David, Bundgaard, Henning, Brunak, Søren, Frikke-Schmidt, Ruth, Holm, Hilma, Sørensen, Erik, Thørner, Lise W, Larsen, Margit A H, Schwinn, Michael, Køber, Lars, Torp-Pedersen, Christian, Ostrowski, Sisse R, Erikstrup, Christian, Nyegaard, Mette, Stefánsson, Hreinn, Gylfason, Arnaldur, Zink, Florian, Walters, G Bragi, Oddsson, Asmundur, Þorleifsson, Guðmar, Másson, Gisli, Thorsteinsdottir, Unnur, Gudbjartsson, Daniel, Pedersen, Ole B, Stefánsson, Kári, Ullum, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719218/
https://www.ncbi.nlm.nih.gov/pubmed/36070241
http://dx.doi.org/10.1136/bmjopen-2021-049709
Descripción
Sumario:PURPOSE: The aim of Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC) is to establish a cohort that can accelerate our understanding of CVD initiation and progression by jointly studying genetics, diagnoses, treatments and risk factors. PARTICIPANTS: The CHB-CVDC is a large genomic cohort of patients with CVD. CHB-CVDC currently includes 96 308 patients. The cohort is part of CHB initiated in 2009 in the Capital Region of Denmark. CHB is continuously growing with ~40 000 samples/year. Patients in CHB were included in CHB-CVDC if they were above 18 years of age and assigned at least one cardiovascular diagnosis. Additionally, up-to 110 000 blood donors can be analysed jointly with CHB-CVDC. Linkage with the Danish National Health Registries, Electronic Patient Records, and Clinical Quality Databases allow up-to 41 years of medical history. All individuals are genotyped using the Infinium Global Screening Array from Illumina and imputed using a reference panel consisting of whole-genome sequence data from 8429 Danes along with 7146 samples from North-Western Europe. Currently, 39 539 of the patients are deceased. FINDINGS TO DATE: Here, we demonstrate the utility of the cohort by showing concordant effects between known variants and selected CVDs, that is, >93% concordance for coronary artery disease, atrial fibrillation, heart failure and cholesterol measurements and 85% concordance for hypertension. Furthermore, we evaluated multiple study designs and the validity of using Danish blood donors as part of CHB-CVDC. Lastly, CHB-CVDC has already made major contributions to studies of sick sinus syndrome and the role of phytosterols in development of atherosclerosis. FUTURE PLANS: In addition to genetics, electronic patient records, national socioeconomic and health registries extensively characterise each patient in CHB-CVDC and provides a promising framework for improved understanding of risk and protective variants. We aim to include other measurable biomarkers for example, proteins in CHB-CVDC making it a platform for multiomics cardiovascular studies.